Name: Insights: Tips From GlaxoSmithKline On How To Streamline Epidemic Vaccine
Uploaded: 2020-03-16
Duration: 3 min 53 s
Description: The global partnership between businesses and governments is trying to get ahead of the next outbreak.

[MUSIC PLAYING] BYRAN WALSH: So Moncef, how can we do it better when we see the next-- it's going to Zika right now and might be something else in a year's time. Both working with the public sector, from your perspective, how do we respond quicker but also I think maybe not let things fall off the agenda the way they sometimes have the past? MONCHEF SLAOUI: Yeah. So we gave this quite a lot of thought. And I would just start by saying last time I took a car insurance, I didn't take it while I was having an accident. I usually take it before. And it's the same principle. what we're proposing is to say for a company like GSK but others have also stepped up but not everyone but others have done to is to say, we as private enterprises hold technologies, know-how, capabilities that have the capacity to save the world. We can't only use them on the purpose of making returns to shareholders. That's what we do on a daily basis. But there are instances where there is a bigger picture. Now the issue is when we are reactive, we have to stop what we do to sustain ourself returning to our shareholders in order to help save the world, whether it's antibiotic resistance or vaccines against pandemics. Let's try to do this in advance of an outbreak. So we made a very specific proposal saying we have platform technologies that we know allow to make vaccines. We know they are safe. And we know how to make them industrial. That's very important. Making a vaccine and running a clinical trial and making a publication in the scientific journal is very important and shows that you can make the vaccine. But you don't have a vaccine for millions of people. The technology is needed to make a vaccine for millions of people over many, many years are very different than those experimental technologies. That's what I call platform technologies. We offered to make these available at no cost to the community. To build an organization, only the cost of running it would be borne by the community. And to put an organization with these platform technologies, with the know-how, et cetera under the governance of an independent body that would, based on science, decides there is a list of 15 or 13 or 11, depending which list you look at, pathogens that are known to be potential outbreak agents. Let's take this organization-- it has about 200 scientists and we sized it and costed it-- and let's have it go after making a vaccine for each one of these pathogens. And the reality will unfold, and an outbreak will happen. And two scenarios are possible. Either we are lucky and we made the vaccine already, in which case we can immediately deploy it. Or we will not likely, we didn't make a vaccine. But here we have an organization has no opportunity cost, it can instantly be fully dedicated with platform technologies that are validated to make as fast as possible a vaccine against a new outbreak. We find this proposal compelling, frankly. Everybody we spoke to found it compelling. It's been two years, great progress-- not as fast as we wish it should be-- has been made. A new organization has been created called CEPI, or Coalition for Epidemic Preparedness Innovation. We're both heavily involved in helping create this coalition. And this coalition could very well be the body that can finance a series of such organizations that can be dedicated proactively, permanently to make vaccines against outbreak agents. 

Insights: Tips From GlaxoSmithKline On How To Streamline Epidemic Vaccine

Uncategorized

The global partnership to get ahead of the next outbreak.

GlaxoSmithKline On How To Streamline Epidemic Vaccine

The global partnership between businesses and governments is trying to get ahead of the next outbreak.

way, do it better. I mean, when we see the next, it's going to be right now. It might be something else in the years time. You know, both working with the public sector from your perspective. How do we respond quicker? But also, I think, you know, maybe not let things fall off the fall of the agenda the way they sometimes had passed. Yes, we get give this quite a lot of thought. And I would just start by saying Last time I took a car insurance. I didn't take it while I was having an accident. I usually take it before, and it's the same principle. What we're proposing is to say for a company like G S K with others have also stepped up. But not everyone but others have done to it to say we have private enterprises, hold technologies, know how capabilities that have the capacity to save the world. We can't on. Lee used them on the purpose of making returns to shareholders. That's what we do on a daily basis. But there are instances where there is a bigger picture. Now the issue is when we're reactive, we have to stop what we do to sustain ourselves, returning to our shareholders in order to help save the world, whether it's antibiotic resistance or vaccines against mimics, let's try to do this in advance of an outbreak. So we made a very specific proposals saying We have platform technology that we know allowed to make vaccines. We know they're safe and we know how to make them industrial. That's very important. Making a vaccine and running a clinical trial and making a publication in Santa Journal is very important and show that you can make the vaccine, but you don't have a vaccine for millions of people. Technology is needed to make a vaccine for millions of people over many, many years are very different than those experimental technologies. That's what I call platform technologies. We offered to make these available at no cost through the community to build an organization, only the cost of running it would be born by the community and to put an organization with these platform technologies with the know how, etcetera under the governance of an independent body that with basil science decide there's a list off 15 or 13 or 11 depending which you look at passages that are known to be potential outbreak agents. Let's take this organization has about 200 scientists and sizes and costed it. Let's have it go after making a vaccine for each one of these pathogens, and the reality will unfold on an outbreak would happen, and two scenarios are possible. Either way, you're lovely and we made the vaccine already, in which case we can immediately deployed or we're not lucky we didn't make a vaccine. But here we have an organization has no part in it because it can instantly be fully dedicated with platform technologies that are validated to make a fastest possible vaccine against a new outbreak. We find this proposal comparing frankly, every body we spoke to found it compelling. It's been two years. Great progress, not as fast as we wish it should be, has been made. A new organization has been created, called Happy or Coalition Coalition for Epidemic Preparedness. Innovation. We're both heavily involved in helping create this coalition on this coalition could very well be the body that can find Siri's off such organizations that can be dedicated proactively, permanently to make vaccines against outbreak agents